GlassScriptPhysician profile
Aubrey Pugh
NPI 1760924211
$10,328.48
in general payments reported to CMS, 2019-2025
33 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.69 · 2022: $2,261 · 2023: $2,435 · 2024: $2,940 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,714 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,713.79 |
| Education | $255.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,925.61 | 2022-2025 | |
| Incyte Corporation | $1,169.73 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,074.45 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $742.52 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $657.81 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $521.32 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $468.10 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $453.70 | 2022-2025 | |
| Organogenesis INC. | $448.79 | 2022-2025 | Puraply, Affinity, Via Matrix |
| Pfizer INC. | $364.61 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $267.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $254.84 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $233.70 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $214.26 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $204.96 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $196.05 | 2022-2024 | Sotyktu |
| Amgen INC. | $166.30 | 2022-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $141.04 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $128.38 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $120.40 | 2023-2025 | |
| Organon LLC | $101.52 | 2025 | Vtama |
| Almirall LLC | $97.08 | 2022-2024 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $87.68 | 2022-2024 | Arazlo, Cabtreo, Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.09 | 2022-2025 | Spevigo, Cyltezo |
| Ani Pharmaceuticals, INC. | $40.81 | 2023 | Apexicon E |
| Fresenius Kabi USA, LLC | $32.99 | 2023 | Idacio |
| Verrica Pharmaceuticals INC. | $29.94 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $24.34 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $22.65 | 2024 | Clindacin Etz |
| Epi Health, LLC | $21.09 | 2022 | |
| Botanix Sb INC | $19.77 | 2025 | Sofdra |
| Kerecis Limited | $13.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biofrontera INC. | $12.89 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Pugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.